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Abstract: Obstacles to effective therapies for mucopolysaccharidoses (MPSs) determine the need
for continuous studies in order to enhance therapeutic strategies. Dimethyl sulfoxide (DMSO) is
frequently utilised as a solvent in biological studies, and as a vehicle for drug therapy and the in vivo
administration of water-insoluble substances. In the light of the uncertainty on the mechanisms of
DMSO impact on metabolism of glycosaminoglycans (GAGs) pathologically accumulated in MPSs,
in this work, we made an attempt to investigate and resolve the question of the nature of GAG
level modulation by DMSO, the isoflavone genistein solvent employed previously by our group in
MPS treatment. In this work, we first found the cytotoxic effect of DMSO on human fibroblasts at
concentrations above 3%. Also, our results displayed the potential role of DMSO in the regulation of
biological processes at the transcriptional level, then demonstrated a moderate impact of the solvent
on GAG synthesis. Interestingly, alterations of lysosomal ultrastructure upon DMSO treatment were
visible. As there is growing evidence in the literature that DMSO can affect cellular pathways leading
to numerous changes, it is important to expand our knowledge concerning this issue.
Keywords: lysosomal storage diseases; mucopolysaccharidosis type III (MPS III; Sanfilippo
syndrome); dimethyl sulfoxide (DMSO); glycosamoninoglycans (GAGs) therapy
1. Introduction
Lysosomal storage diseases (LSDs) are a group of over 50 rare inherited metabolic disorders
that appear from defects in lysosomal function, leading usually to deficiency of a single enzyme
required for the metabolism of lipids, glycoproteins or glycosaminoglycans (GAGs) [1,2]. Alterations
in the metabolism of GAGs due to mutations in genes coding for enzymes involved in degradation
of these compounds cause severe inherited metabolic diseases known as mucopolysaccharidoses
(MPSs). Impaired hydrolysis of GAGs leads to their accumulation in cells of patients, which results in
a progressive damage of the affected tissues and organs, including the heart, respiratory system, bones,
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joints and central nervous system (CNS) [3]. Remarkably, studies of the neurodegeneration process in
MPSs have shown increased levels of protein markers of Alzheimer’s disease and other tauopathies in
brain areas involved in learning and memory (primarily dentate gyrus and medial entorhinal cortex)
of MPS IIIA, MPS IIIB [4] and MPS IIIC mice [5].
Bone marrow or haematopoietic stem cell transplantations and enzyme replacement therapy
(ERT) are the only approved treatments for MPS [6]. However, neurological symptoms, developing due
to GAG accumulation in CNS, cannot be managed by ERT owing to an inefficient delivery of proteins
through the blood–brain barrier (BBB) [7]. Among a few different therapeutic strategies, for example,
gene therapy or direct delivery of the enzyme in the cerebrospinal fluid, some other approaches
can be distinguished [8]. To this end, a small inhibitory molecule prone to penetrating the BBB is
employed. Together with the presence of about 3% of the residual activity of particular hydrolase,
this proposal allows restoration of the balance in the metabolism of macromolecules, which leads to the
lack of stored material within lysosomes. Implementation of this strategy is called substrate reduction
therapy (SRT) [9]. The efficiency of this rationale has been observed using the flavonoid genistein
(5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) in Sanfilippo disease, and miglustat
(Zavesca®) in Gaucher disease [10]. Many investigations have revealed that due to pleiotropic effects,
genistein can be used to modulate pivotal mechanisms in human cells, for instance, the cell cycle [11],
metabolism of macromolecules [12] or biogenesis and activity of lysosomes [13,14]. Because patients
suffering from different types of MPSs have many defects in cellular processes as mentioned above,
this isoflavone is considered as a novel therapeutic agent, especially in a combination therapy with
an enzyme.
One of the important aspects of our research work so far, in which we tested genistein for
implementation in MPS treatment, was to use a solvent appropriate for this substance, which is at
the same time well tolerated by the human body during consumption. Dimethyl sulfoxide (DMSO),
a by-product of the wood industry, has been used as a commercial solvent since 1953, while the history
of DMSO as a pharmaceutical began in 1961 [15,16]. From this time, it has been frequently utilised as
a diluent in biological studies and as a vehicle for drug therapy and in the in vivo administration of
water-insoluble substances. DMSO has been used successfully in many human therapeutic situations,
such as in the treatment of interstitial cystitis, dermatological, urinary, pulmonary, rheumatic and renal
manifestations, amyloidosis, gastrointestinal diseases, musculoskeletal disorders and rheumatologic
and dermatologic diseases, as a topical analgesic, and others [17,18]. Importantly, DMSO crosses the
BBB [19]; thus, it has been effective in the treatment of traumatic brain oedema [20]. This feature is not
without significance even when it comes to using it as a solvent for substances that are to cross the BBB,
such as genistein utilised in the treatment of LSDs with neurological manifestation. DMSO is known as
an agent affecting GAG synthesis and excretion [21–23], and changes in the biochemical composition
of DMSO-treated cells with regard to sulfated and nonsulfated GAGs have been observed [24]. On the
other hand, the side effects of DMSO, apparent from its use in the laboratory (both in vitro and in vivo)
and in clinical settings, are reported [18], though its mechanisms of action have not yet been fully
elucidated. These are often simply neglected; therefore, when working with DMSO, one might be
aware of the experience of other groups who are using it, even in very varied contexts.
The first reports indicated inhibition of GAG synthesis by DMSO in Chinese hamster ovary (CHO)
cells [24] and in HLH60/HGPRT leukaemia cells. According to Constantopoulos et al., DMSO inhibits
cell proliferation, but also GAG synthesis and secretion in cultured glioma [25] and this effect was
comparable to results observed in rat prostate adenocarcinoma [22]. Surprisingly, in the same study,
adenocarcinoma cells that acquired the capacity to grow in higher DMSO concentration secreted
excessive amounts of glycosaminoglycans.
In the light of the above-described facts and uncertainty on the mechanisms of DMSO regulation
of GAG metabolism, in this work we have tried to resolve the question of the nature of GAG level
modulation by DMSO, the genistein solvent employed by our group in MPS treatment.
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2. Results
2.1. Cytotoxicity of DMSO in In Vitro Cell Cultures
DMSO is usually well tolerated with no observable toxic effects to cells at 0.1% final concentration
and is widely used as a solvent for various pharmacological agents at concentrations of 0.05–1.5%.
Thus, to test the influence of DMSO on human dermal fibroblasts, HDFa and MPS IIIA and IIIB,
viability and proliferation, we selected concentrations from 0.01% to 5% v/v.
After 24 h of culture, DMSO concentrations of 3% v/v had little cytotoxic effect on tested cells,
and inhibited growth to 81%, compared to untreated control culture (Figure 1). Exposure of cultures
for 48 h to concentrations reaching 1% v/v DMSO had no significant effect, and cell viability was even
increased, as revealed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay.
DMSO at 3% and 5% v/v concentration reduced cell growth in both times of exposure to 81% and 55%,
and 60% and 44%, respectively.
After seven days, fibroblast proliferation was reduced 85% and 57% in case of 1% and 2% v/v
DMSO, while 3% v/v resulted in 16% of viability and 5% concentration was lethal for the whole culture.
DMSO at 0.01%, 0.05%, 0.1% and 0.5% v/v had no impact on cell growth and proliferation.
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Figure 1. Cell viability following exposure to DMSO. Cells were grown in medium supplemented 
with increasing DMSO concentrations for 24 h (A), 48 h (B) or 7 days (C). Cell viability was assessed 
in MTT assay and was calculated as relative to control cells grown in culture medium without DMSO. 
Values represent means of at least two independent experiments (each run in triplicate) with bars 
representing standard deviation. Statistical significance was tested by one-way ANOVA followed by 
Tukey’s multiple comparison test; * p < 0.05 and ** p < 0.01 vs. control cells without DMSO treatment. 
2.2. Fibroblast Gene Expression Profiling upon DMSO Treatment 
Microarray studies of the impact of DMSO on HDFa transcriptome with Illumina’s Human HT-
12 v4 Expression BeadChips were performed for DMSO concentration, 0.05% v/v, most frequently 
applied when used as a solvent. This assumption was based on medium impact of DMSO at higher 
concentrations on processes like GAG synthesis. Gene expression analysis revealed 285, 201 and 256 
differentially expressed genes (DEGs) upon 1, 24 and 48 h exposure, respectively, to 0.05% v/v DMSO, 
compared to untreated control (Table 1). Within these genes, more than 87% had upregulated 
expression after 1 and 24 h treatment: 249 and 176, respectively. In the case of 48 h exposure to DMSO, 
the effect was more balanced, reaching ca. 58% and 42% for up- and downregulated genes, 148 and 
108, respectively. Moreover, we found a few genes with expression modulated after more than one 
time period (Figure 2), with SURF2 expression changed under all conditions. Typically, for the whole 
analysis, modulation of gene expression was rather moderate, with minimum and maximum changes 
around 0.5- and 2-fold, respectively (Table 2), but it was difficult to define common biological 
processes for the products of genes with mostly altered expression. 
Figure 1. Cell viability following exposure to DMSO. Cells were grown in medium supplemented with
increasing DMSO concentrations for 24 h (A), 48 h (B) or 7 days (C). Cell viability was assessed in
MTT assay and was calculated as relative to control cells grown in culture medium without DMSO.
Values represent means of at least two independent experiments (each run in triplicate) with bars
representing standard deviation. Statistical significance was tested by one-way ANOVA followed by
Tukey’s multiple comparison test; * p < 0.05 and ** p < 0.01 vs. control cells without DMSO treatment.
2.2. Fibroblast Gene Expression Profiling upon DMSO Treatment
Microarray studies of the impact of DMSO on HDFa transcriptome with Illumina’s Human
HT-12 v4 Expression BeadC ips were performed for DMSO con entration, 0.05% v/v, most frequently
applied when used as a solvent. This assumption was based on medium impact of DMSO at higher
concentratio s on proce ses like GAG ynthesis. Gene expression analysis revealed 285, 201 and
256 differentially expressed genes (DEGs) upon 1, 24 and 48 h exposure, respectively, to 0.05% v/v
DMSO, compared to untr ated control (Table 1). Within these gen s, more than 87% had upregulated
expression after 1 and 24 h treatment: 249 and 176, resp ctively. In the case of 4 h exposure to DMSO,
the effect was more balanced, reaching ca. 58% and 42% for up- and downregulated gen s, 148 and
108, respectively. Moreover, we found a few genes with expression m dulated fter more than o e
time period (Figure 2), with SURF2 expression changed under all conditions. Typically, f r the whol
analysis, modulation of gene expression was rat er moderat , with minimum and maximum changes
round 0.5- and 2-f ld, respectively (Table 2), but it was ifficult to defi e common biological process s
for the products of genes with mostl altered expression.
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Table 1. Selected significantly overrepresented GO terms upon HDFa treatment with 0.05% DMSO.
AmiGO analysis and Panther Classification System defined mostly enriched molecular functions,
biological processes, cellular components and protein classes upon 0.05% DMSO HDFa treatment for 1,
24 and 48 h with false discovery rate (FDR) < 0.1, fold change (FC) ≤ 0.7 (blue columns) and ≥1.3 (red
columns), n = 3 and p < 0.001. Each column represents numbers of DEGs involved in defined term and
percentage gene hits against total number of genes (in brackets). Number of all overrepresented GO
terms for each time point and class is presented in square brackets.
Number of DEGs in Term
GO Term 1 h 24 h 48 h
Molecular Function [5] [7] [2] [7] [6] [8]
binding (GO:0005488) 10 (29.4%) 73 (31.1%) 4 (19.0%) 35 (22.0%) 27 (26.5%) 37 (27.0%)
catalytic activity (GO:0003824) 8 (23.5%) 53 (22.6%) 3 (14.3%) 44 (27.7%) 23 (22.5%) 35 (25.5%)
transporter activity (GO:0005215) 1 (2.9%) 9 (3.8%) 4 (2.5%) 8 (7.8%) 5 (3.6%)
signal transducer activity (GO:0004871) 1 (2.9%) 8 (3.4%) 2 (1.3%) 3 (2.9%) 4 (2.9%)
receptor activity (GO:0004872) 1 (2.9%) 12 (5.1%) 7 (4.4%) 2 (2.0%) 2 (1.5%
structural molecule activity (GO:0005198) 1 (2.9%) 7 (3.0%) 3 (1.9%) 3 (2.2%)
translation regulator activity
(GO:0045182) 3 (1.3%) 2 (1.3%) 3 (2.2%)
Biological Process [9] [13] [9] [12] [11] [11]
metabolic process (GO:0008152) 15 (44.1%) 79 (33.6%) 6 (38.1%) 54 (34.0%) 33 (32.4%) 52 (38.0%)
cellular process (GO:0009987) 11 (32.4%) 113 (48.1%) 8 (28.6%) 70 (44.0%) 45 (44.1%) 52 (38.0%)
cellular component organization or
biogenesis (GO:0071840) 2 (5.9%) 27 (11.5%) 2 (9.5%) 20 (12.6%) 5 (4.9%) 16 (11.7%)
biological regulation (GO:0065007) 3 (8.8%) 38 (16.2%) 4 (19.0%) 19 (11.9%) 10 (9.8%) 17 (12.4%)
response to stimulus (GO:0050896) 3 (8.8%) 32 (13.6%) 2 (9.5%) 16 (10.1%) 9 (8.8%) 15 (10.9%)
developmental process (GO:0032502) 27 (11.5%) 2 (9.5%) 16 (10.1%) 11 (10.8%) 8 (5.8%)
localization (GO:0051179) 2 (5.9%) 26 (11.1%) 10 (6.3%) 9 (8.8%) 13 (9.5%)
multicellular organismal process
(GO:0032501) 19 (8.1%) 10 (6.3%) 4 (2.9%)
Cellular Component [4] [7] [3] [7] [5] [7]
cell part (GO:0044464) 8 (23.5%) 84 (35.7%) 4 (19.0%) 44 (27.7%) 29 (28.4%) 49 (35.8%)
organelle (GO:0043226) 6 (17.6%) 63 (26.8%) 4 (19.0%) 28 (17.6%) 21 (20.6%) 35 (25.5%)
membrane (GO:0016020) 1 (2.9%) 27 (11.5%) 11 (6.9%) 10 (9.8%) 16 (11.7%)
macromolecular complex (GO:0032991) 1 (2.9%) 30 (12.8%) 3 (14.3%) 12 (7.5%) 5 (4.9%) 19 (13.9%)
extracellular region (GO:0005576) 7 (3.0%) 7 (4.4%) 3 (2.9%) 3 (2.2%)
Protein Class [5] [22] [5] [16] [19] [18]
transcription factor (PC00218) 5 (14.7%) 24 (10.2%) 2 (9.5%) 8 (5.0%) 8 (7.8%) 7 (5.1%)
nucleic acid binding (PC00171) 4 (11.8%) 30 (12.8%) 2 (9.5%) 14 (8.8%) 7 (6.9%) 19 (13.9%)
hydrolase (PC00121) 3 (8.8%) 17 (7.2%) 1 (4.8%) 8 (5.0%) 5 (4.9%) 11 (8.0%)
transferase (PC00220) 2 (5.9%) 19 (8.1%) 1 (4.8%) 10 (6.3%) 5 (4.9%) 10 (7.3%)
enzyme modulator (PC00095) 10 (4.3%) 6 (3.8%) 7 (5.1%)
receptor (PC00197) 9 (3.8%) 1 (4.8%) 7 (4.4%) 3 (2.9%)
transporter (PC00227) 7 (3.0%) 5 (3.1%) 7 (6.9%) 5 (3.6%)
signaling molecule (PC00207) 9 (3.8%) 7 (4.4%) 6 (5.9%) 7 (5.1%)
transfer/carrier protein (PC00219) 1 (2.9%)
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There were also only a few genes differentially expressed after DMSO treatment whose products
are involved in lysosomal, glycosaminoglycan or sphingolipid metabolism pathways (Table 3).
Denoted modulation in expression level was around 0.6–0.7 and 1.3–1.7 for down- and upregulation,
respectively. The products of positively regulated transcripts might be mainly classified under
glycan biosynthesis and metabolism, glycosphingolipid biosynthesis, sphingolipid metabolism and
sphingosine biosynthesis, while the products of negatively regulated transcripts might be involved in
lysosomal metabolism, with special focus on ZKSCAN3, a master repressor of autophagy.
DMSO is frequently used in liver cell cultivation and is thought to affect the expression of various
cytochrome P450 (CYP450) isoforms by inducing or preserving cellular differentiation. In the course of
our analysis, no changes were seen in the expression level of genes coding for CYP450, which were
observed in cases of human, rat and murine hepatocytes. But as has been shown, human dermal
fibroblasts express low levels of CYP [26].
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Table 2. Expression level of selected genes with the most changed activity profile after 1, 24 and 48 h
treatment with 0.05% DMSO of HDFa. Normalised to untreated cells, relative genome microarray
values ± standard deviation from n = 3 denote differences for samples incubated with 0.05% DMSO.
Alterations in mRNA levels of genes are referred to FC ≤ 0.7 (A) and FC ≥ 1.3 (B) with the
p-value < 0.05.
(A)
Time of Exposure to DMSO
1 h 24 h 48 h
Gene Expression Modulation
BBS12 0.58 ± 0.07 ACVRL1 0.60 ± 0.11 ALG2 0.60 ± 0.08
CDKN1C 0.60 ± 0.11 APEG1 0.63 ± 0.15 ANKRD26 0.64 ± 0.14
DDIT4 0.51 ± 0.10 ATF2 0.66 ± 0.02 ANKRD38 0.51 ± 0.15
EBF1 0.67 ± 0.05 CCDC15 0.68 ± 0.12 ATP7B 0.62 ± 0.17
FLJ10246 0.56 ± 0.08 CHODL 0.60 ± 0.14 BAIAP2L1 0.66 ± 0.12
FLJ45244 0.63 ± 0.11 EDNRA 0.61 ± 0.06 BEX2 0.59 ± 0.09
GM2A 0.61 ± 0.07 FAM21A 0.65 ± 0.12 DAK 0.59 ± 0.10
HCFC2 0.63 ± 0.06 GGT7 0.68 ± 0.05 DHRSX 0.61 ± 0.15
HSPA1L 0.57 ± 0.08 LMNB1 0.60 ± 0.04 DKFZp761P0423 0.61 ± 0.04
KCNJ2 0.62 ± 0.06 MCPH1 0.67 ± 0.03 DNAJC1 0.57 ± 0.08
KIAA0100 0.63 ± 0.18 MFHAS1 0.66 ± 0.00 DNAJC3 0.65 ± 0.02
KRCC1 0.66 ± 0.09 PTHLH 0.68 ± 0.07 EIF2C4 0.55 ± 0.04
LIAS 0.64 ± 0.02 RNF141 0.69 ± 0.02 FAM127C 0.66 ± 0.19
LZTFL1 0.67 ± 0.01 SNORD16 0.55 ± 0.02 FAM83H 0.52 ± 0.06
MGA 0.62 ± 0.11 SSX2IP 0.69 ± 0.00 FKBPL 0.59 ± 0.12
NICN1 0.63 ± 0.09 SURF2 0.67 ± 0.08 FLJ11151 0.62 ± 0.10
PLAC9 0.65 ± 0.02 TAF13 0.68 ± 0.13 FLJ23834 0.66 ± 0.04
SLC40A1 0.66 ± 0.02 WIPF2 0.65 ± 0.01 FLJ35220 0.64 ± 0.10
SPIN1 0.67 ± 0.03 ZKSCAN3 0.67 ± 0.01 FLJ90086 0.60 ± 0.02
TAOK1 0.67 ± 0.10 ZNF417 0.67 ± 0.10 FRY 0.61 ± 0.09
(B)
Time of Exposure to DMSO
1 h 24 h 48 h
Gene Expression Modulation
ALG2 1.64 ± 0.27 BMP6 1.65 ± 0.20 ADAM9 1.62 ± 0.33
ANKS3 1.62 ± 0.02 FAM113B 1.61 ± 0.21 APCDD1L 1.59 ± 0.47
BET1L 1.60 ± 0.23 GFOD1 1.73 ± 0.29 BHLHB2 1.56 ± 0.21
CDC42EP3 2.04 ± 0.04 GSTM5 1.55 ± 0.25 CXCL1 1.70 ± 0.03
CDK8 1.59 ± 0.19 ITGBL1 1.79 ± 0.53 ERCC4 1.54 ± 0.41
DENND2C 1.60 ± 0.15 KCNJ16 1.55 ± 0.35 ETV3 1.73 ± 0.41
F5 1.59 ± 0.01 KIAA0746 1.80 ± 0.08 GFM2 1.69 ± 0.06
FLJ30058 1.60 ± 0.27 LENG8 1.73 ± 0.19 GNAQ 1.59 ± 0.26
GALNAC4S-6ST 1.69 ± 0.45 MEGF8 1.72 ± 0.51 HES4 1.58 ± 0.33
GRK6 1.63 ± 0.37 MESP1 1.64 ± 0.38 HPS3 1.54 ± 0.14
KLF10 1.90 ± 0.11 MT1G 1.62 ± 0.27 KLF10 1.66 ± 0.32
LMAN2 1.70 ± 0.19 MTE 1.55 ± 0.46 MAGEL2 1.65 ± 0.45
MAP6D1 1.59 ± 0.45 NAP1L3 1.57 ± 0.32 OXCT1 1.65 ± 0.23
MYBBP1A 1.66 ± 0.48 NDNL2 1.66 ± 0.47 PMS2 1.80 ± 0.34
NR4A1 1.74 ± 0.25 NEFM 1.53 ± 0.37 SNORD31 1.78 ± 0.41
SPIN2B 1.62 ± 0.46 SLC38A4 1.69 ± 0.07 SNX12 1.73 ± 0.17
TJP2 1.84 ± 0.36 STAC 1.61 ± 0.13 SPG21 1.57 ± 0.45
UBA2 1.65 ± 0.20 STK11 1.55 ± 0.05 STIM2 1.58 ± 0.19
UBA3 1.60 ± 0.27 ZBBX 1.55 ± 0.02 TBC1D23 1.55 ± 0.43
ZNF597 1.62 ± 0.22 ZSCAN16 1.54 ± 0.21 TMEM161A 1.76 ± 0.24
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Table 3. Expression patterns of GAG metabolism- and lysosome-associated genes in HDFa treated with 0.05% DMSO for 1, 24 and 48 h, identified in microarray and
real-time qRT-PCR analyses (bolded are values of FC ≤ 0.7 and FC ≥ 1.3, n = 3, with the p-value < 0.05).
Gene Expression Term Genes
1 h 24 h 48 h
FC± SD FC± SD FC± SD
Microarray Real-Time qRT-PCR Microarray Real-Time qRT-PCR Microarray Real-Time qRT-PCR
Upregulation
Glycan biosynthesis and
metabolism
B4GALT1 0.83 ± 0.0 0.81 ± 0.0 1.32± 0.1 1.34± 0.3 0.94 ± 0.0
GALNT2 1.46± 0.2 1.38± 0.1 1.08 ± 0.1 1.12 ± 0.1 1.01 ± 0.4
GALNT4 1.50± 0.2 1.39± 0.1 0.87 ± 0.1 0.93 ± 0.1 1.34± 0.2 1.05 ± 0.0
GALNT6 1.11 ± 0.1 1.17 ± 0.1 0.91 ± 0.0 0.91 ± 0.0 1.31± 0.1 1.27 ± 0.1
GALNT12 1.33± 0.1 1.29 ± 0.0 0.83 ± 0.0 0.91 ± 0.1 1.26 ± 0.0
MAN2C1 1.37± 0.0 1.42± 0.0 0.90 ± 0.1 1.01 ± 0.1 0.78 ± 0.1
N-Glycan biosynthesis ALG12 1.12 ± 0.4 1.30± 0.1 1.40± 0.0 1.08 ± 0.2 0.78 ± 0.2 1.19 ± 0.1
CS/DS biosynthesis CHST15 1.7± 0.4 1.73± 0.1 1.14 ± 0.4 1.00 ± 0.2 0.98 ± 0.0
HS synthesis EXT1 1.46± 0.1 1.48± 0.0 0.94 ± 0.0 0.83 ± 0.1 0.88 ± 0.3 0.99 ± 0.0
KS biosynthesis B4GALT1 0.83 ± 0.0 0.81 ± 0.0 1.32± 0.1 1.34± 0.0 0.94 ± 0.0CHST2 1.42± 0.1 1.15 ± 0.5
GAG (CS, KS) degradation GALNS 1.03 ± 0.2 0.98 ± 0.1 1.37± 0.3 1.42± 0.2 1.25 ± 0.1 1.02 ± 0.0
SL metabolism
SGPL1 1.34± 0.0
1.31± 0.3
1.18 ± 0.3 0.88 ± 0.0
SPTLC2 0.95 ± 0.0 0.91 ± 0.1 1.01 ± 0.0 1.48± 0.4 1.31± 0.1
SPTLC3 1.17 ± 0.0 1.31± 0.3 1.41± 0.2 1.37± 0.1
GSLs biosynthesis
B4GALT1 0.83 ± 0.0 0.81 ± 0.0 1.32± 0.1 1.34± 0.0 0.94 ± 0.0
ST3GAL5 1.32± 0.2 1.32± 0.0 1.09 ± 0.1 1.03 ± 0.1 0.89 ± 0.0 0.97 ± 0.0
SLC7A5 1.32± 0.1 1.30± 0.0 1.21 ± 0.5 1.07 ± 0.0 1.06 ± 0.0
Sphingosine biosynthesis SPTLC2 0.95 ± 0.0 0.91 ± 0.1 1.02 ± 0.2 1.01 ± 0.0 1.48± 0.4 1.31± 0.1SPTLC3 1.17 ± 0.0 1.31± 0.3 1.41± 0.2 1.37± 0.1
Lysosome ARSK 0.83 ± 0.2 1.11 ± 0.6 1.14 ± 0.0 1.37± 0.1 1.44± 0.5
Downregulation
N-Glycan biosynthesis ALG2 1.64 ± 0.3 1.61± 0.1 0.97 ± 0.2 0.99 ± 0.0 0.60± 0.1 0.92 ± 0.0
Lysosome GM2A 0.61± 0.1 0.58± 0.0 0.98 ± 0.0 0.99 ± 0.0 1.60± 0.1
MCOLN1 1.01 ± 0.2 0.99 ± 0.0 0.97 ± 0.0 0.99 ± 0.0 0.68± 0.2 0.81 ± 0.1
Master repressor of autophagy ZKSCAN3 0.51± 0.0 0.67± 0.0 0.92 ± 0.0 0.69± 0.2 0.88 ± 0.0
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2.3. Gene Ontology (GO) Analysis of DMSO-Modulated Transcripts
Results of DEGs analysis with AmiGO [27] and the Panther Classification System [28] ranked the
list of GO terms with percentage of gene hits against total number of analysed genes with modulated
expression. In all tested conditions, GO annotations for groups of differentially expressed genes
were mostly repetitive (Table 1), both in the case of same type modulation but also between up- and
downregulated gene sets.
Molecular function was mostly represented by binding (GO:0005488) and catalytic activity
(GO:0003824): 19–29% and 14–23% for downregulated genes, respectively. At approximately similar
levels, those annotations were enriched for upregulated genes, reaching 22–31% and 22–28% for
binding and catalytic activity, respectively. Transporter activity (GO:0005215) and signal transducer
activity (GO:0004871) were also common for all up- and downregulated gene sets, besides fold change
(FC) of ≤0.7 for 24 h incubation with 0.05% DMSO, but with a minor contribution (1.3–7.8%).
Biological processes were predominantly exhibited by cellular process (GO:0009987) and metabolic
process (GO:0008152), ranging from 38–48% and 33–34% for upregulated genes, and 32–44%
and 29–44% for negatively-regulated genes, respectively. Other shared processes were biological
regulation (GO:0065007), cellular component organisation or biogenesis (GO:0071840), response
to stimulus (GO:0050896), developmental process (GO:0032502), localisation (GO:0051179) and
multicellular organismal process (GO:0032501), with gene hit against total number of genes around
10%, (precisely 3–19%) for all analysed gene sets.
Cellular component analysis revealed cell part (GO:0044464) and organelle (GO:0043226) to
be mostly represented between all gene sets: 28–36% and 18–27% for up- and 19–28% and 18–20%
for downregulated genes, respectively. Also in this shared group was macromolecular complex
(GO:0032991) with 7–14% and 3–14% gene hits, for up- and downregulated genes, respectively.
For positively modulated transcripts in common were also extracellular region (GO:0005576) and
extracellular matrix (GO:0031012) with 1–4% enrichment.
Major distinguishable protein classes coded by modulated genes were transcription factor
(PC00218), nucleic acid binding (PC00171), hydrolase (PC00121) and transferase (PC00220),
representing between 7% and 15% of whole transcripts. Upregulated genes were also classified as
enzyme modulator (PC00095), signalling molecule (PC00207), receptor (PC00197), cytoskeletal protein
(PC00085), transporter (PC00227), extracellular matrix protein (PC00102), cell adhesion molecule
(PC00069), as were downregulated genes from samples treated with DMSO for 48 h. All these groups
were enriched by 1–7%. Worthy of mention is the high number of genes assigned as transcription
factor, signalling molecule and receptor, which may have special impacts on cell metabolism.
Although GO analysis indicated many pathways related to genes with modulated activity,
especially for positive modulation (44 pathways for 1 h treatment with DMSO, 60 for 24 h and 35 for
48 h, with 249, 176 and 148 upregulated genes, respectively, for particular conditions), each pathway
was represented by only 1–3 genes. Only a limited number of pathways were enriched with more
than five genes, as in analysis of transcripts with upregulated expression upon 1 h and 24 h DMSO
treatment. While the percentage of gene hits against total number of genes did not exceed 5% (with only
one exception: 9.5% for downregulated gene set analysis after 24 h DMSO incubation), no prevalent
pathways were distinguished.
Gene Set Enrichment Analysis [29] did not reveal any gene sets significantly enriched at
FDR < 25%. One of the reasons may be a small number of DEGs.
2.4. Kinetics of GAG Synthesis upon DMSO Treatment in MPS and HDFa Fibroblasts
No significant differences in GAG synthesis level (10–20%) have been observed upon treatment
with low DMSO concentrations; however, higher concentrations, 2% and 3%, resulted in 20–60%
reduction in GAG synthesis, depending on the cell line tested (Figure 3). The most substantial
reduction, 61%, was noted for MPS IIIA fibroblasts upon treatment with 3% DMSO. A statistically
significant decrease in glucosamine, D-[1-3H] incorporation was achieved only for MPS IIIA and B
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fibroblasts cultivated with 3% DMSO (Kruskal–Wallis test followed by Dunn–Bonferroni post hoc;
* p < 0.05) and versus control cells without DMSO treatment.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW  9 of 18 
 
fibroblasts cultivated with 3% DMSO (Kruskal–Wallis test followed by Dunn–Bonferroni post hoc; * 
p < 0.05) and versus contr l cells without DMSO treatment. 
 
Figure 3. Kinetics of GAG synthesis upon DMSO treatment. Relative level of glycosaminoglycan 
synthesis in HDFa, MPS IIIA and fibroblasts after 72 h treatment with different concentrations of 
DMSO measured by incorporation of [3H]GlcN. Values represent means of at least two independent 
experiments (each run in triplicate) with bars representing standard deviation. Statistical significance 
was tested by Kruskal–Wallis test followed by Dunn–Bonferroni post hoc; * p < 0.05 and vs. control 
cells without DMSO treatment. 
2.5. Electron Microscopy Studies of Lysosomal Compartment 
Transmission electron microscopy (TEM) of MPS patient and control fibroblasts enabled 
visualisation of lysosomes (L), carbohydrate storing lysosomes (LC), lysosomes of amorphous 
flocculent and electron dense structure (LD) and autophagosomal vacuoles (AV). Mean numbers of 
lysosomal structures per 100 μm2 cell cross-section are presented (Figure 4). Organelles of special 
interest were LC, due to potential GAG storage. 
The most notable changes in fibroblast ultrastructure were seen at the highest DMSO 
concentration tested (3%); however, this treatment also resulted in visible alterations in cell 
morphology. The most prevalent organelles denoted were single lysosomes. A concentration-
dependent increase in the number of these structures per cell was observed in MPS IIIA (panel A), 
and even more in HDFa cell cultures (panel C). In contrast, a subtle decrease was seen in MPS IIIB 
fibroblasts (besides almost 50% increase for 0.05% v/v DMSO compared to untreated control) (panel 
B). The accumulation of structures morphologically defined as carbohydrate-storing lysosomes was 
rather minor even in MPS cells, and any changes in this vesicle number were difficult to define. The 
number of lysosomes that accumulated electron-dense structure was slightly concentration 
dependently decreased in MPS IIIB and HDFa fibroblast, while in MPS IIIA, it was constant. In the 
case of AVs, we observed an increase in this fraction for MPS IIIB and HDFa fibroblasts, with no 
differences in MPS IIIA cells. TEM analysis did not reveal any significant differences in the size of 
lysosomal structures, other than LCs in 3% DMSO-treated HDFa, which were visibly larger. 
Examples of lysosomal structures occurring in MPS cells are presented in Figure 4. 
Figure 3. Kinetics of AG synthesis upon DMSO treatment. Relative level of glycosaminoglycan
synthesis in HDFa, MPS IIIA and fi roblasts after 72 h treatment with different concentrations of
DMSO measured by inc rporati n of [3H]GlcN. Values represent means of at least two independent
experiments (each run in triplicate) with bars representing stan ard deviation. Statistical significance
was tested by Kruskal–Wallis test followed by Dunn–Bonferroni post hoc; * p < 0.05 and vs. control
cells without DMSO treatment.
2.5. Electron Microscopy Studies of Lysosomal Compartment
Transmission electron microscopy (TEM) of MPS patient and control fibroblasts enabled
visualisation of lysosomes (L), carbohydrate storing lysosomes (LC), lysosomes of amorphous
flocculent and electron dense structure (LD) and autophagosomal vacuoles (AV). Mean numbers
of lysosomal structures per 100 µm2 cell cross-section are presented (Figure 4). Organelles of special
interest were LC, due to potential GAG storage.
The most notable changes in fibroblast ultrastructure were seen at the highest DMSO concentration
tested (3%); however, this treatment also resulted in visible alterations in cell morphology. The most
prevalent organelles denoted were single lysosomes. A concentration-dependent increase in the
number of these structures per cell was observed in MPS IIIA (panel A), and even more in HDFa
cell cultures (panel C). In contrast, a subtle decrease was seen in MPS IIIB fibroblasts (besides almost
50% increase for 0.05% v/v DMSO compared to untreated control) (panel B). The accumulation of
structures morphologically defined as carbohydrate-storing lysosomes was rather minor even in MPS
cells, and any changes in this vesicle number were difficult to define. The number of lysosomes that
accumulated electron-dense structure was slightly concentration dependently decreased in MPS IIIB
and HDFa fibroblast, while in MPS IIIA, it was constant. In the case of AVs, we observed an increase
in this fraction for MPS IIIB and HDFa fibroblasts, with no differences in MPS IIIA cells. TEM analysis
did not reveal any significant differences in the size of lysosomal structures, other than LCs in 3%
DMSO-treated HDFa, which were visibly larger. Examples of lysosomal structures occurring in MPS
cells are presented in Figure 4.
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3. Discussion
Research on the implementation of the nonenzymatic SRT using GAG metabolism
modulators to treat MPSs wi h neurological symptoms is one of the investigation concepts
ini iated with various flavonoids [7,8]. We demonstrated previously that natural flavonoids,
such as genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-be zopyran-4-on), kaempferol
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cells and fibroblasts of MPS p tients and mic [7,8,30]. SRT co d be ef ective in the management
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of CNS-related symptoms of MPS, especially if a small molecule, capable of crossing the BBB,
is employed.
Since DMSO has been widely used as a vehicle for the delivery of various molecules in
cultured cells, in vivo experiments and in medicine (particularly for conditions such as scleroderma,
and rheumatoid- and osteoarthritis), it is worth verifying more deeply its potential impact on biological
processes such as glycosaminoglycan biosynthesis.
3.1. Cytotoxic Effect of DMSO on Human Fibroblasts at Higher Concentrations
In the course of our studies, there was no cytotoxic effect of DMSO in concentrations similar to
those commonly assumed as safe and routinely used in cell cultures [31]. DMSO concentrations up to
3% v/v were well tolerated by HDFa. Similar results were obtained in goat skin fibroblasts, where cells
survived beyond 3% DMSO, but concentrations regarded as higher (0.5–3% v/v) led to reductions in
cell viability in a dose-dependent manner. In many studies, 0.1% v/v DMSO in growth media was
established as the safest, while DMSO concentrations more than 1% v/v have been shown to be toxic
for most mammalian cell types when used in in vitro culture assays. Even so, certain studies have
shown that lower concentrations of DMSO (0.05–0.2% v/v) may enhance proliferation in some cell
types, such as ovarian cancer cells [32]. In fibroblasts obtained from Niemann–Pick patients, cellular
division was blocked and DMSO above 2% v/v was cytotoxic [33].
3.2. Potential Role of DMSO in Regulation of Biological Processes on Transcriptional Level
DMSO is generally considered to be genetically inactive and is thus very frequently used
as a solvent in drug-screening assays. In concentrations of 1.5–5% v/v, or even 10% v/v, it is
frequently applied to induce differentiation of various cell lines [34], including fibroblasts [31,32].
Differentiation of fibroblasts into myofibroblasts is one of the key factors for wound healing and is
accompanied by release of several types of cytokine [33]. The results of Morley and Whitfield suggest
that DMSO-induced Ca2+ release from intracellular stores may play a role in the induction of cell
differentiation in primary cultures and in cells of a variety of established lines [35]. However, the ability
of DMSO to induce cell differentiation indicated that this compound might exert an influence at the
genetic regulation level; by gene ontology analysis conducted in the course of our studies, we did not
find any pathways or biological processes connected to cell differentiation (Table 1). Gene expression
analysis for sequences with most modulated expression did not derive any specified common process
or cellular pathway. It must be emphasized that for 0.05% v/v DMSO, changes in transcriptional level
were rather subtle, with fold change value 0.6–0.7 and 1.3–1.7 for down- and upregulation, respectively
(Tables 2 and 3). Importantly, both microarray and real-time qRT-PCR analyses of GAG metabolism-
and lysosome-associated genes gave similar results, indicating accuracy of both methods (Table 3). Also,
percentage of modulated transcripts was minor and ranged less than 1% of well-defined sequences.
The only gene that appeared to be regulated at all three time points was SURF2, a housekeeping gene,
but expression modulation was rather subtle.
Among the biological processes enriched in the present analysis, the predominant were the
metabolic process (GO:0008152) and cellular process (GO:0009987), where nearly 40% of modulated
transcripts were involved. Nevertheless, the impact on the biological regulation (GO:0065007) process
might be crucial, with 5.9–16.2% genes showing altered expression, and also protein class GO terms,
such as transcription factor (PC00218) and nucleic acid binding (PC00171), showing 5–14.7% and
6.9–13.9% of modulated transcripts, respectively. For molecular function, the most enriched terms were
binding (GO:00054888) and catalytic activity (GO:0003824), where 19–31.1% and 14.3–27.7% of genes
with altered expression were involved, respectively. All these results display the potential role of DMSO
in regulation of biological processes at the transcriptional level as a transcription factor modulator.
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3.3. Moderate DMSO Impact on GAG Synthesis
One open question remained the influence of DMSO on the synthesis of glycosaminoglycans.
The results of our research performed on fibroblasts provided by MPS patients and on healthy
controls displayed GAG synthesis reduction, but only for higher (above 1% v/v) DMSO concentrations.
The obtained data were not statistically significant. Furthermore, gene expression analysis followed by
GO revealed only few DEGs involved in GAG metabolism what might be due to applied concentration
of DMSO, 0.05%, that did not result in GAG synthesis reduction. No significant enrichments in cellular
components or biological processes, such as lysosome or lysosomal biogenesis, besides ZKSCAN3,
an inhibitor of autophagy, were noted, which might indicate no impact of DMSO on GAG degradation
at this concentration, either. All these data demonstrate low impact of DMSO on GAG synthesis
modulation at concentrations employed when it is used as a solvent for biological applications.
Treatment of rat prostate adenocarcinoma PAIII cells with 1.5% DMSO decreased both the secretion
of GAGs into the medium and also the incorporation of [3H]glucosamine into the cellular GAG level.
However, in cells adapted to higher DMSO concentrations (2.5% v/v), PAIII-DMSO, the quantity of
GAGs secreted into the medium was increased to approximately twice the level of untreated PAIII cells.
In unadapted PAIII cells, exposure to 2.5% v/v DMSO reduced the amount of GAGs shedding into
the culture medium to 18% of control values [22]. Those differences presented between rat prostate
adenocarcinoma cells resistant to high DMSO concentrations and the parental line suggest selection of
a genetically diverse subpopulation or induction of a compensation mechanism by constant exposure
to DMSO. While in the course of our studies modulation of GAG synthesis was estimated only on the
basis of cellular content, some difficulties may arise in analysis of the examined solvent effect. Here,
the cellular level of synthesised GAGs was decreased.
The effect of DMSO was studied also on another lysosomal storage disorder, Niemann–Pick
disease (NPD) type B and C. Sphingomyelinase (SMase) activity in human skin fibroblasts from NPD
patients was increased up to 230% of control by 2% v/v DMSO, while the cell growth was inhibited.
Other lysosomal hydrolases displayed a rather inconsiderable increase in activity [36] and the effects
of DMSO on sphingomyelinase activity in fibroblasts from Niemann–Pick type B patients were less
than those of a type C. Comparable results were obtained from studies with NPD type B GM 3393 cell
line and indicated that activities of lysosomal hydrolases, especially β-galactosidase, were found to be
upregulated. However, observed changes in the levels of the activities of these enzymes after DMSO
treatment were still lower than the DMSO-induced increase in SMase activity in cells from normal and
type C patients [37].
3.4. Alterations of Lysosomal Ultrastructure upon DMSO Treatment
Previous electron microscopy reports on fibroblasts from MPS patients revealed the accumulation
of enlarged vacuolar structures containing glycosaminoglycans and lipids forming characteristic
multiconcentric lamellae. Analysis was performed in the course of this study of both MPS and HDFa
with TEM-enabled visualisation of representative lysosomal structures. It is worth noting that we
observed a concentration-dependent decrease in the number of carbohydrate-storing electron lucent
lysosomes (LCs) mostly in MPS IIIBa and HDFa, but also in MPSIIIA fibroblasts after six-day exposure
to DMSO, with highest reductions in 0.5% and 1% DMSO concentrations relative to untreated controls
(Figure 4). In MPS IIIB and HDFa cells, treatment with those concentrations resulted in an almost
undetectable level of carbohydrate-storing lysosomes. This result might be crucial, as electrolucent
LCs seem to be lysosomes loaded with GAGs. There was also noticeable increase in the number of
lysosomes, indicating upregulated lysosomal metabolism, detected especially in HDFa, but also in
MPS IIIA cells. MPS IIIB fibroblasts have shown considerably higher numbers of single lysosomes
for 0.05% DMSO only, while in the case of MPS IIIA and HDFa, at this concentration, there were no
differences from the untreated control. The decrease in the number of carbohydrate-storing lysosomes
was comparable to that achieved in studies on the influence of selected flavonoids and their derivatives
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on GAG storage in MPS cell lines [7,27,38,39], where the potential therapeutic efficacy of natural
compounds was tested.
4. Materials and Methods
4.1. Cell Lines, Culture Media, Supplements and Flavonoid Solutions
HDFa (Cascade Biologics, Portland, OR, USA) and MPS IIIA and IIIB fibroblasts (Children’s
Memorial Health Institute, Warsaw, Poland) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Sigma-Aldrich, Steinheim, Germany) supplemented with 10% foetal bovine serum (FBS)
and 1% antibiotic/antimycotic solution (Sigma-Aldrich, Steinheim, Germany), 5% CO2 at 37 ◦C.
For experimental procedures, cells at passages were plated to a confluency of approximately 80% and
grown at 37 ◦C in humid atmosphere containing 5% CO2.
4.2. Cytotoxicity and Proliferation Assay
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was performed to
estimate cell growth and proliferation. HDFa cells were seeded 6 × 103 per well (in cytotoxicity
assay) or 103 cell per well (in proliferation assay) in flat-bottomed, 96-well plates and treated with
0.01%, 0.05%, 0.1%, 0.5%, 1% and 5% v/v DMSO as control for 24 h, 48 h, and 7 days at 37 ◦C.
After the incubation period, the medium was replaced with RPMI (Sigma-Aldrich) supplemented
with MTT (1 mg/mL) for another 4 h. The purple formazan crystals were dissolved in 150 µL DMSO,
and absorbance was determined at 570 nm using a Wallac 1420 Multilabel Counter (Perkin Elmer,
Waltham, MA, USA).
4.3. RNA Extraction
Total RNA was extracted using the High Pure RNA Isolation Kit (Roche Applied Science,
Indianapolis, IN, USA) following the manufacturer’s instructions. The quality and quantity of each
RNA sample was evaluated using the RNA 6000 Nano Assay on an Agilent 2100 Bioanalyser (Agilent
Technologies Inc., Agilent Technologies, Loveland, CO, USA).
4.4. Microarray Assays for mRNA Analysis
Whole genome microarray analysis of three biological replicates (n) was performed using
Illumina’s Human HT-12v3 Expression BeadChips, for more than 47,000 genes and sequences (Illumina
Inc., San Diego, CA, USA) as reported in our previous publication [13]. 1 × 105 HDFa cells were
seeded and grown overnight and then treated with 0.05% DMSO for 1, 24 and 48 h, assigned formerly
as vehicle control (K2), followed by RNA isolation. Cells harvested in medium nonsupplemented
with DMSO were treated as control, formerly named pure control, K1. The assay performance,
data extraction and statistical analysis were performed as previously described [13]. Genes with FC
expression greater than or equal to 1.3 or lower than or equal to 0.7 were described as modulated.
Gene Ontology analysis and data visualisation were performed on the upregulated and downregulated
gene lists separately, using the web tools GOrilla (http://cbl-gorilla.cs.technion.ac.il/) restricting the
output to biological process, molecular function and protein class. Additionally, AmiGO [27] GO
analysis tool, together with Panther Classification System [28], were applied to verify biological process,
molecular function, cellular component and pathways (Biocarta, KEGG, Reactome, GO_biological
process, GO_cellular component) represented by groups of genes with modulated expression. Gene Set
Enrichment Analysis (GSEA) was performed as previously described [29]. A nominal p-value < 0.01
and a false discovery rate (FDR) <0.25 were used to assess the significance of the enrichment scores.
The microarray expression data used in this study had GEO accession numbers GSE34074 [13].
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4.5. Real-Time qRT-PCR Assays for mRNA Analysis
Quantitative real-time Reverse Transcription PCR (real-time qRT-PCR) was performed to
measure the mRNA levels of the genes coding for GAG and lysosomal metabolism. Total RNA
was reverse-transcribed into cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche
Applied Science, Indianapolis, IN, USA), according to the manufacturer’s instructions. Real-time
qRT-PCR was carried out with TaqMan Gene Expression Assays (Thermo Fisher Scientific,
Foster City, CA, USA) with catalog numbers as follows: #4426961 (Hs00904548_m1, ALG2),
#4331182 (Hs00970128_m1, ALG12), #4331182 (Hs00406036_m1, ARSK), #4331182 (Hs00155245_m1,
B4GALT1), #4331182 (Hs01921028_s1, CHST2), #4331182 (Hs00248144_m1, CHST15), #4331182
(Hs00609162_m1, EXT1), #4331182 (Hs00975732_m1, GALNS), #4331182 (Hs00189537_m1, GALNT2),
#4331182 (Hs00559726_s1, GALNT4), #4331182 (Hs99999909_m1, GALNT6), #4331182 (Hs00226436_m1,
GALNT12), #4448892 (Hs00166197_m1, GM2A), #4331182 (Hs00428900_m1, MAN2C1), #4331182
(Hs01100653_m1, MCOLN1), #4331182 (Hs00393705_m1, SGPL1), #4331182 (Hs01001189_m1, SLC7A5),
#4331182 (Hs01027014_m1, SPTLC2), #4331182 (Hs00217867_m1, SPTLC3), #4331182 (Hs01105377_m1,
ST3GAL5), #4331182 (Hs00383244_m1, ZKSCAN3), using the Light Cycler 480 II detection system
(Roche Applied Science, Indianapolis, IN, USA). Expression values were normalised against three
control genes GAPDH, TBP and YWHAZ of constant expression level under experimental conditions
(2−∆∆Ct method). Determination of reference genes for real-time qRT-PCR was based on BestKeeper
software analysis. While for all three implemented housekeeping genes, expression levels were
comparable, data presented in Table 2 are fold-change normalised to GAPDH. For both DNA microarray
and real-time qRT-PCR analyses, a fold change greater or equal to 1.3 and below and equal 0.7 was
considered as a relevant criterion for genes being significantly differentially expressed, with a p-value
of <0.05.
4.6. Measurement of Kinetics of GAG Synthesis
The kinetics of GAG synthesis was estimated by measurement of incorporation of glucosamine,
D-[1-3H] (3H-GlcN) (Hartmann Analytic GmbH, Braunschweig, Germany) into GAG chains. HDFa
and MPS cells were plated 2 × 104 per well in a 48-well plate and incubated overnight to allow
attachment. Cells were then preincubated for 48 h in standard DMEM supplemented with appropriate
amounts of DMSO or in DMEM only (control cultures) and then labelled for 24 h with 10µCi/mL
of 3H-GlcN in DMEM without glucose and pyruvate (Thermo Fisher Scientific Inc., Paisley, UK)
supplemented with 10% FBS and with or without DMSO.
After labelling, cells were washed six times with Dulbecco’s phosphate-buffered saline
(DPBS, Thermo Fisher Scientific Inc., Paisley, UK) and digested for 3 h at 65 ◦C with 0.5%
papain (Sigma-Aldrich Co. LLC., St. Louis, MO, USA) (prepared in 200 mM phosphate buffer
(Na2HPO4–NaH2PO4), pH 6.4, containing 100 mM sodium acetate, 10 mM Na2EDTA and 5 mM
L-cysteine). Incorporation of 3H-GlcN was measured in a MicroBeta2 scintillation counter (Perkin
Elmer Inc., Waltham, MA, USA) and Quant-iT™ PicoGreen® dsDNA reagent was used to determine
DNA concentration in papain-digested samples. Incorporation of radioactive precursors was calculated
per DNA amount (cpm/ng of DNA) and expressed as relative to control cultures (without treatment).
To test the efficiency of DMSO on the kinetics of GAG synthesis, Kruskal–Wallis test was performed
with Dunn–Bonferroni as a post hoc comparator with significance declared at p < 0.05 versus control
cells without DMSO treatment.
4.7. Transmission Electron Microscopy (TEM)
In order to determine the effect of DMSO on cellular structures with special focus on the lysosomal
system, 1.5× 105 HDFa and MPS III cells were plated in 12-well plates and allowed to attach overnight.
Cells were then treated with DMSO at final concentrations 0.05%, 0.1%, 0.5%, 1%, 2% and 3% v/v and
incubated for six days. Following PBS washing, cells were fixed with 2.5% glutaraldehyde, and then
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with 1% osmium tetroxide and 1% potassium hexacyanoferrate (III) followed by ethanol dehydration.
Ultrasections of cells embedded in Epon 812 resin (Fluka Chemie GmbH, Buchs, Switzerland) were
stained in lead citrate and uranyl acetate and examined under TEM (Philips CM100). All fibroblasts
photographed using TEM program (Olympus Soft Imaging Solution, Münster, Germany) had intact
membrane and visible cell structures (nucleus, mitochondria and lysosomes). At least 20 cells
were examined and for each cell at least five random fields were assessed. Lamellar lysosomes
and complex lysosomal structures (Figure 4) were counted by an individual blind to experimental
conditions, per 100 µm2 cross-section of cell structures. Representative electron micrographs are shown
at magnification 1650×.
5. Conclusions
As a result of our research, we managed to point out the role of dimethyl sulfoxide (DMSO) in
gene expression modulation and glycosaminoglycan metabolism in lysosomal storage disorders on an
example of mucopolysaccharidosis. In this report, we have tried to answer the question being asked
and move forward to get further information and a better understanding of the problem.
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